NEWRON PHARMACEUTICALS SPA (NP5.DE) Stock Earnings & Estimates
Europe - Frankfurt Stock Exchange - FRA:NP5 - IT0004147952 - Common Stock
18.06 EUR
+1.68 (+10.26%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.094M 5.76% | 9.057M 48.62% | 51.39M 467.41% | 17.239M -66.45% | 13.477M -21.82% | 14.244M 5.69% | 184.49M 1,195.21% | 212.48M 15.17% | 203.15M -4.39% | 247.72M 21.94% | 276.74M 11.71% | |
| EBITDA YoY % growth | -13.1M -7.84% | -11.428M 12.76% | 26.365M 330.71% | -17.976M -168.18% | -19.543M -8.72% | -7.268M 62.81% | 152.36M 2,196.46% | 176.2M 15.65% | 162.73M -7.64% | 204.18M 25.47% | 230.1M 12.69% | |
| EBIT YoY % growth | -13.302M -7.65% | -11.629M 12.58% | 26.173M 325.07% | -18.549M -170.87% | -20.057M -8.13% | -7.931M 60.46% | 152.36M 2,021.19% | 176.2M 15.65% | 162.73M -7.64% | 204.18M 25.47% | 230.1M 12.69% | |
| Operating Margin | -218.28% | -128.40% | 50.93% | -107.60% | -148.82% | -55.68% | 82.58% | 82.93% | 80.10% | 82.42% | 83.15% | |
| EPS YoY % growth | -0.98 -16.67% | -0.91 7.14% | 0.85 193.41% | -1.12 -231.20% | -1.20 -7.93% | -0.42 64.83% | 4.77 1,226.34% | 5.52 15.87% | 5.45 -1.31% | 6.90 26.62% | 7.65 10.81% |
All data in EUR
| Q2 / 25 | Q4 / 25 | Q2 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.45 100.00% | -0.70 -151.75% | -0.58 | -0.95 -34.78% |
| Revenue Q2Q % growth | 9.119M 249.22% | 3.876M -91.92% | N/A | N/A |
| EBITDA Q2Q % growth | -5.855M 22.83% | -11.383M -133.43% | N/A | N/A |
| EBIT Q2Q % growth | -5.957M 22.47% | -11.485M -133.92% | N/A | N/A |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 0.00 100.00% | -0.45 | 0.45 | 100.00% |
| Q4 2024 Q2Q % growth | 1.36 361.54% | 1.95 | -0.59 | -30.19% |
| Q2 2024 Q2Q % growth | -0.51 -30.77% | -0.51 | 0.00 | 0.00% |
| Q4 2023 Q2Q % growth | -0.52 -4.00% | -0.50 | -0.02 | -4.04% |
| Q2 2023 Q2Q % growth | -0.39 18.75% | -0.58 | 0.19 | 32.92% |
| Q4 2022 Q2Q % growth | -0.50 -51.52% | -0.54 | 0.04 | 7.51% |
| Q2 2022 Q2Q % growth | -0.48 5.88% | -0.45 | -0.03 | -6.95% |
| Q4 2021 Q2Q % growth | -0.33 44.07% | -0.63 | 0.30 | 47.39% |
| Q2 2021 Q2Q % growth | -0.51 13.56% | -0.59 | 0.08 | 13.79% |
| Q4 2020 Q2Q % growth | -0.59 -73.53% | -0.71 | 0.12 | 17.37% |
| Q2 2020 Q2Q % growth | -0.59 25.32% | -0.73 | 0.14 | 19.66% |
| Q4 2019 Q2Q % growth | -0.34 | -0.81 | 0.47 | 57.81% |
| Q2 2019 Q2Q % growth | -0.79 | -0.70 | -0.09 | -12.25% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 11.898M 249.22% | 9.119M | 2.779M | 30.47% |
| Q4 2024 Q2Q % growth | 47.983M 1,246.70% | 48.654M | -671K | -1.38% |
| Q2 2024 Q2Q % growth | 3.407M -37.99% | 3.672M | -265K | -7.22% |
| Q4 2023 Q2Q % growth | 3.563M 9.16% | 3.468M | 95K | 2.74% |
| Q2 2023 Q2Q % growth | 5.494M 94.13% | 3.264M | 2.23M | 68.32% |
| Q4 2022 Q2Q % growth | 3.264M 5.60% | 3.274M | -10K | -0.31% |
| Q2 2022 Q2Q % growth | 2.83M 5.95% | 3.264M | -434K | -13.30% |
| Q4 2021 Q2Q % growth | 3.091M 12.44% | 3.06M | 31K | 1.01% |
| Q2 2021 Q2Q % growth | 2.671M 6.46% | 2.55M | 121K | 4.75% |
| Q4 2020 Q2Q % growth | 2.749M -42.80% | 2.958M | -209K | -7.07% |
| Q2 2020 Q2Q % growth | 2.509M 12.41% | 2.856M | -347K | -12.15% |
| Q4 2019 Q2Q % growth | 4.806M | 4.488M | 318K | 7.09% |
| Q2 2019 Q2Q % growth | 2.232M | 2.88M | -648K | -22.50% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 0% | 33.2% |
| Revenue | N/A | N/A | 0% | 44.98% |